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Abstract
BACKGROUND & AIMS—Crohn’s disease (CD) and ulcerative colitis (UC) are major forms of 
inflammatory bowel disease (IBD) and pathogenesis involves a complex interplay between 
genetic, environmental and immunological factors. We evaluated isoform expression of the IL-12-
activated transcription factor STAT4 in children with CD and UC.
METHODS—We performed a study where we collected biopsy samples from both newly 
diagnosed CD and UC patients. We further collected blood samples from newly diagnosed CD 
and UC patients as well as patients who had a flare-up after being in clinical remission, and 
examined the ratios of STAT4β/STAT4α mRNA. In addition to STAT4 isoforms we measured the 
expression of the cytokines TNFα, IFNγ, GM-CSF and IL-17 using PCR of biopsy samples and 
multiplex analysis of patient serum samples.
RESULTS—Ratios of STAT4β/STAT4α were increased in specific GI tract segments in both CD 
and UC patients that correlate with location and severity of inflammation. In contrast, we did not 
observe changes in STAT4β/STAT4α ratios in biopsy specimens from eosinophilic esophagitis 
patients. We also observed increased STAT4β/STAT4α ratios in the peripheral blood 
mononuclear cells of UC and CD patients, compared to healthy controls. Ratios were normalized 
after patient treatment with steroids.
CONCLUSIONS—Collectively, these data indicate that STAT4 isoforms could be an important 
non-invasive biomarker in the diagnosis and treatment of IBD, and that expression of these 
isoforms might provide further insight into the pathogenesis of IBD.
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INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC) are two predominant forms of 
inflammatory bowel disease (IBD) in humans, characterized by chronic inflammation of the 
gastrointestinal tract. CD mainly affects the ileum and colon but can involve any region of 
the gastrointestinal tract in a discontinuous fashion. In contrast, inflammation in UC 
involves colon, typically starting distally at the rectum and extending proximally in a 
continuous manner for a variable distance. IBD may present at any age although it occurs 
primarily during the second and third decades of life, especially during adolescence 1–3. IBD 
symptoms include diarrhea, severe abdominal pain, gastrointestinal bleeding, weight loss 
and fatigue, all of which may substantially affect patient’s quality of life and account for 
considerable costs to the health care system 4–6. The incidence of IBD is increasing 
worldwide, with the age of presentation progressively decreasing. 7–10.
The pathogenic mechanisms of IBD are unclear although both genetic and environmental 
factors have major roles. Available evidence suggests that in genetically susceptible 
individuals, a dysregulated mucosal immune response against antigens from normal gut 
flora triggers disease. This uncontrolled response results in excessive proinflammatory 
cytokine accumulation leading to mucosal inflammation. T cells play a crucial role in 
mediating mucosal inflammation; Th1 and Th17 cells mediate CD whereas UC exhibits Th2 
and Th17 characteristics 11–14. Patients with CD show increased production of IFNγ, a Th1 
cell associated cytokine, from lamina propria and lymph node T cells. Furthermore, lamina 
propria T cells from CD patients exhibit increased expression of IL12Rβ2, a Th1 cell surface 
receptor 15–17. In contrast, lamina propria T cells from UC patients have been shown to 
produce IL-5 and IL-13 11, 18, 19. More recently, IL-9, a Th9 cytokine, was shown to be 
involved in pathogenesis of UC 20, 21.
The involvement of Th17 cells in both forms of disease is complicated by pleiotropic effects 
of the cytokines they produce. Several groups have reported a role of cytokines associated 
with the Th17 subset in IBD, including increases of IL-17A, IL-17F, IL-22, IL-26, and 
CCL20 in samples from patients with active disease 13, 22–27. However, the effects of 
IL-17A in disease are multi-faceted. Hueber et al showed that blocking IL-17A by 
secukinumab (anti-IL-17A monoclonal antibody) had no beneficial effects in patients with 
moderate or severe Crohn’s disease 28. Friedrich et al showed that psoriatic skin of anti-TNF 
treated patients had significant increases in epidermal IL-36γ and IL-17A levels, suggesting 
a crucial role for this cytokine pair in the pathogenesis of anti-TNF induced skin 
inflammation 29. However, in a murine T cell transfer model of colitis, protective effects of 
IL-17A were demonstrated 30. Thus, the effects of Th17 cytokines in the development of 
IBD are complex and likely vary with the amount of inflammation.
STAT4 (Signal transducer and activator of transcription 4) is predominantly expressed in 
hematopoietic cells, is critical for the development of Th1 cells, promotes IL-17 production 
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from Th17 cells and also plays an essential role in various immune-mediated diseases 31–36. 
STAT4 is predominantly activated by IL-12 and to a lesser extent by type I interferons and 
IL-23 31. Genetic association studies have shown that the STAT4 gene is significantly 
associated with IBD in Spanish and Caucasian populations 37–39. STAT4 is constitutively 
expressed in intestinal T cells of CD patients and there are increased levels of 
phosphorylated STAT4 in the mucosal cells of UC patients 35, 36. Increased mucosal 
expression of STAT4 has also been reported in pediatric UC but no significant difference 
was observed in pediatric CD patients 40. In mouse models of IBD, STAT4 is required for 
the development of disease, and transgenic expression of STAT4 promotes disease 41–44. 
Thus, evidence suggests a mechanistic link between STAT4 and IBD.
STAT4 is expressed as two isoforms, a full-length STAT4α, and a shorter form termed as 
STAT4β that lacks the C-terminal transactivation domain 45. The beta isoform is generated 
from an mRNA where the last intron of the STAT4 mRNA is not spliced out, followed by 
cleavage and polyadenylation of transcript proximal to the final exon encoding the 
transactivation domain (Fig. 1). The protein is translated by read-through of the final intron 
leading to generation of STAT4 lacking the C-terminal domain but containing a unique 
seven amino acid tag 45. The beta isoform is generally expressed in lower amounts than the 
alpha isoform, but is activated for a longer period of time following IL-12 stimulation 44, 45. 
Using a transfer colitis model, we demonstrated that although both isoforms mediate IBD, 
STAT4β promotes more severe colonic inflammation and tissue destruction that correlates 
with TNF-α and GM-CSF expression 44. The aim of this study was to explore whether 
STAT4 isoforms are differentially expressed in the gut and PBMCs of pediatric CD and UC 
patients and if this differential expression correlates with disease severity.
Materials and Methods
Study Subjects and Sample collection
Our study focused on four groups of patients; new CD patients, new UC patients, and 
established CD or UC patients that had disease recurrence. Inclusion criteria for patients 
were a new diagnosis of CD or UC where the physician had not initiated yet any treatment 
(for new patients) or a recurrence of disease (for established disease). Patients were above 
age 7 and under age 18 and had received a clinical diagnosis in the past 21 days. 
Approximately 4 ml blood was drawn from newly diagnosed CD or UC patients who had 
yet to receive any treatment on their first visit to the clinic and also on their 2nd visit, two 
weeks following corticosteroid treatment. For established CD or UC patients, blood was 
drawn on their initial visit to the clinic as well as two weeks after their initial infliximab 
treatment. Infliximab is a recombinant chimeric immunoglobulin G monoclonal antibody 
that neutralizes the biologic activity of TNFα and is approved for treatment of pediatric CD 
and UC patients46. Infliximab dosage given to these pediatric patients was 5 mg/kg/dose. 
We also enrolled 12 healthy volunteers in our study that did not suffer from any chronic or 
acute inflammatory disease and the control patients indicated in Figures 2 and 3 are the same 
population. The clinical profiles of patients are listed in Table 1 and more detailed clinical 
descriptions including Paris classifications is shown in Supplementary Table 1 47.
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Mucosal biopsy samples from new patients were obtained from esophagus, stomach, 
duodenum, terminal ileum, colon, cecum and rectum in newly diagnosed UC (N=5) and CD 
(N=9). Biopsies from control subjects were obtained from individuals undergoing 
colonoscopy but had no disease upon pathological examination (N=5) and were a separate 
group from the PBMC controls described above. Biopsies were immediately stored at −80 
°C until processing.
Esophageal biopsies were obtained from children with EoE (diagnosed as ≥15 eosinophils 
per hpf on esophageal biopsies in absence of gastroesophageal reflux and/or lack of response 
to proton-pump inhibitor therapy). EoE patients (n=14) had an average eosinophil count per 
hpf of 55; were 45.5% male and had an average age of 12.8 years (range, 4–17.5). Matched 
controls (n=13) did not have eosinophils in biopsies as part of a clinical diagnosis, were 50% 
male, and had an average age of 11.9 (range 4–17.5). Esophageal biopsies from children 
with EoE and corresponding age-matched healthy controls were processed as described 
below.
Ethical considerations
The IRB of Indiana University approved the study and informed consent for participation in 
this study was obtained from parents of all the children enrolled in the study.
Isolation of peripheral blood mononuclear cells
Blood samples were obtained from new patients and patients with recurrent disease before 
and after treatment. Peripheral blood mononuclear cells (PBMCs) were isolated from blood 
using a Ficoll-paque Plus (GE Healthcare). PBMCs were washed by gently mixing the white 
interphase layer with sterile phosphate buffered saline. Cells were counted by trypan blue 
staining and were stored in DMSO-freezing media in liquid nitrogen.
Cytokine measurement
To detect multiple cytokine levels in serum samples from children with IBD, we performed 
the Multiplex Bead Immunoassay as per manufacturer’s instructions (Millipore, Saint 
Charles, Mo) using a Luminex 200 instrument (Luminex orporation, Austin, Texas). 
Cytokine concentrations were calculated using Bio-plex manager 2.3 software with a five 
parameter curve-fitting algorithm applied for standard curve calculations. The minimal 
cytokine detection limit is 3.2 pg/ml; the frequency of non-detection was zero for all 
cytokines.
RNA Extraction, cDNA synthesis and Quantitative RT-PCR
RNA was extracted from frozen tissue samples of CD, UC patients or normal controls as 
well as from PBMCs using Trizol reagent according to manufacturer’s instructions 
(Invitrogen, CA). 2ug of RNA per sample were reverse-transcribed into cDNA. Expression 
of STAT4 isoforms and GM-CSF was evaluated using Sybr Green based RT-PCR. Primer 
sequences were as follows: Stat4 alpha forward 5`- TAT CCT GAC ATT CCC AAA GAC 
-3` reverse 5`- CTC TCA ACA CCG CAT ACA CAC -3`; Stat4 beta forward 5` - TAT CCT 
GAC ATT CCC AAA GAC -3` reverse 58 GAC TTA CTA TGT CAG GAA CTC -3`. 
TNFα, IFNγ, IL-17 and STAT4 were analyzed using commercially available TaqMan 
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probes with an ABI PRISM 7500 Sequence Detection System (Applied Biosystems). 
Expression levels of each gene were normalized to GAPDH.
Statistical Analysis
Statistical analyses were performed using the nonparametric Kruskal-Wallis test and the 
Mann-Whitney U-test in the GraphPad Prism. Results were considered as statistically 
significant when p-values were ≤ 0.05.
Results
STAT4β/α mRNA ratios are significantly increased in CD patient biopsies
To determine if the expression of STAT4 isoforms is altered in patients with IBD, we used a 
quantitative PCR approach to distinguish between the alpha and beta transcripts (Fig. 1). We 
first analyzed biopsy tissue from newly diagnosed pediatric CD patients and observed 
increased expression levels of STAT4 mRNA in ileum and colon regions of the 
gastrointestinal tract when compared with healthy controls and other regions of the GI tract 
(Fig. 2A). We also found that STAT4β/α mRNA ratios were significantly increased in CD 
patients when compared with healthy controls, specifically in the duodenum, ileum, cecum 
and colon, regions of the gut that are most affected by inflammation (Fig. 2B). The smaller 
magnitude of increase of STAT4β/α mRNA ratios in the cecum corresponded to lower 
amounts of total STAT4 in that segment (Fig. 2A–B). We further examined the expression 
of T cell-produced cytokines that have been linked to CD. TNFA showed a trend towards 
increased expression in the colon but was not significantly increased (Fig. 2C). IFNG 
expression was elevated in ileum and cecum regions of the gut, but was only significantly 
increased in colon and rectum (Fig. 2D). IL17A expression was significantly increased in the 
cecum and colon, and surprisingly in the esophagus (Fig. 2E). In contrast, although there 
was increased expression in some patient samples, we did not observe a statistically 
significant increase in the expression of granulocyte macrophage-colony stimulating factor 
(CSF2) (Fig. 2F).
STAT4β/α mRNA ratios are significantly increased in UC patient biopsies
We next assessed the biopsies of UC patients and healthy controls by quantitative RT-PCR 
for total STAT4 and STAT4β/α mRNA ratios. Although there was no statistically 
significant difference in the total STAT4 mRNA expression, we did observe significantly 
increased STAT4β/α mRNA ratios in the cecum, colon and rectum (Fig. 3A–B). TNFA, 
CSF2, and IFNG expression were not significantly increased in UC patients, consistent with 
limited Th1 cell involvement in UC (Fig. 3C, D, F). In contrast, IL17A expression was 
significantly increased in the rectum of the UC patients when compared with healthy 
controls, and as in the CD samples, IL17A was also significantly increased in esophagus 
(Fig. 3E).
STAT4β/α mRNA ratios are not increased in EoE patient biopsies
To determine if increased STAT4β/α mRNA ratios were a common feature to any 
inflammatory disease in the GI tract, we examined biopsy samples from children with 
eosinophilic esophagitis (EoE) and controls that were examined for reflux symptoms but did 
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not have esophageal inflammation. In contrast to CD and UC, EoE is characterized by 
allergic inflammation and increased expression of Th2 cytokines 48. There was no 
significant difference in the STAT4β/α mRNA ratios between controls and patients with 
EoE (Supplementary Figure 1). This suggests that there is specificity for increases in 
STAT4β/α mRNA ratios among types of gastrointestinal inflammation.
Human peripheral blood mononuclear cells express increased STAT4 isoform ratios
Having observed increased STAT4β/α mRNA ratios in biopsy samples from CD and UC 
patients, we next wanted to determine if altered ratios were also observed in immune cells in 
the periphery. To test this, we purified PBMC RNA isolated from newly diagnosed CD and 
UC patients, and age-matched control groups. Newly diagnosed CD patients had modestly 
but significantly increased expression of total STAT4 as well as had significantly more 
STAT4β/α mRNA ratios compared to PBMCs from age-matched controls without any 
diagnosed autoimmune disease (Fig. 4A–B). However, newly diagnosed UC patients had 
only significantly elevated STAT4β/α mRNA ratios and had no significant difference in the 
levels of total STAT4 mRNA (Fig. 4A–B). Importantly, when newly diagnosed CD or UC 
patients were treated with steroids for a two-week period, STAT4β/α mRNA ratios were 
reduced in parallel to a decreased Pediatric Crohn’s Disease Activity Index (PCDAI) or UC 
index (Fig. 4B–D).
In patients with established disease tested before and after infliximab treatment following a 
recurrence in inflammation, we observed that total STAT4 levels were elevated at the first 
visit in CD patients though this was not correlated with an increase in STAT4β/α mRNA 
ratios, and that treatment did not significantly alter ratios (Fig. 4E–F). In contrast, STAT4 
mRNA in UC patients was not altered, but STAT4β/α mRNA ratios were elevated and 
treatment with infliximab significantly decreased ratios to levels observed in control samples 
(Fig. 4E–F).
Serum pro-inflammatory cytokine levels in CD and UC patients
To determine if altered STAT4β/α mRNA ratios correlated with changes in serum cytokine 
concentrations, we analyzed serum from control, CD and UC patients. Newly diagnosed CD 
patients had significant increases in TNF-α (Fig. 5A). Recurrent CD patients had increases 
in TNF-α, IFN-γ, GM-CSF, and although the groups were not different, some recurrent CD 
patients had increased IL-17A concentrations (Fig. 5A–D). Newly diagnosed UC patients 
had increased TNF-α and IFN-γ, whereas recurrent UC patients did not have significant 
increases in any cytokine concentrations (Fig. 5). We did not observe any significant 
differences in IL-12 levels among the various groups, although some individual patients 
clearly had increased IL-12 compared to controls (Fig. 5E).
Correlation of the STAT4β/α ratio with disease severity
To determine if there was a relationship between the STAT4β/α mRNA ratios and disease 
score, we tested the correlation in data from biopsy samples. We observed that STAT4β/α 
mRNA ratios from the colon (Fig. 2) were positively correlated with patient scores for the 
PCDAI (r2=0.53, p=0.027) (Fig. 6). However, we did not observe a significant association 
of STAT4β/α mRNA ratios in tissue from duodenum, ileum, or cecum, despite the 
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significant elevation of STAT4β/α mRNA ratios at those sites (Fig. 2). We saw a similar 
relationship between STAT4β/α mRNA ratios determined from PBMCs (Fig. 4) and PCDAI 
(r2=0.41, p=0.05).
We did not observe any significant association between any of the cytokine mRNA amounts 
and PCDAI, nor was there an association between STAT4β/α mRNA ratios and cytokine 
mRNA. Despite there being increased STAT4β/α mRNA ratios in UC patient biopsies and 
PBMCs, we did not observe any significant correlation between STAT4β/α mRNA ratios 
and UC disease severity.
DISCUSSION
Crohn’s disease (CD) and ulcerative colitis (UC) are the two most common immune-
mediated gastrointestinal diseases and share overlapping genetic risk variants. Despite 
significant progress in the field, much of the etiology of IBD still remains unresolved. 
Furthermore not all patients respond to the current therapeutic molecules. Incidence of IBD, 
particularly pediatric IBD is increasing; hence there is an urgent need for new therapeutic 
approaches as well as new diagnostic markers. In the current study, we investigated the 
expression of STAT4 isoforms in CD and UC. We have previously demonstrated in our 
murine model that although both STAT4α and STAT4β were able to promote inflammation, 
STAT4β was more efficient in promoting inflammation44. Our results here demonstrate that 
STAT4β/STAT4α mRNA ratios are significantly increased in biopsies and PBMCs from 
both CD and UC and use of ratios in PBMCs suggests a novel non-invasive marker for 
diagnosis of disease severity.
It is still unclear whether the alteration in STAT4β/α mRNA ratios is a result of the IBD, or 
if altered ratios actually play a role in promoting inflammation. From mouse models of 
colitis and experimental autoimmune encephalomyelitis, STAT4β is more proinflammatory 
than the STAT4α isoform 44, 49. Although T cells expressing either STAT4α or STAT4β 
had similar IFN-γ production, T cells expressing only STAT4β had greater production of 
GM-CSF and TNF-α 44. T cells expressing only STAT4α had increased IL-10 production, 
correlating with diminished inflammatory potential 49. The functional link between STAT4 
isoform expression and altered inflammatory potential would suggest that altered ratios 
would lead to altered function of cells in vivo. A causative link between increased 
STAT4β/α mRNA ratios in biopsies, or from PBMC RNA, and disease is further supported 
by the correlation of ratios with disease severity, at least in CD patients upon initial 
diagnosis.
The ability of steroid or infliximab treatment to decrease the STAT4β/α mRNA ratios in 
PBMCs suggests that the inflammatory environment increases STAT4β/α mRNA ratios. In 
some preliminary experiments, we observed that stimulation of PBMCs with various 
cytokines present in patients with autoimmune disease leads to altered STAT4β/α mRNA 
ratios. This might suggest a feed-forward loop where increased STAT4β/α mRNA ratios 
result in more pro-inflammatory cytokine production, and increased concentrations of pro-
inflammatory cytokines reinforce changes in STAT4β/α mRNA ratios. It is also possible 
that there are genetic predispositions to altered STAT4β/α mRNA ratios. Although there are 
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no disease-associated SNPs in the region spanned by exons 18–19, the rs925847 SNP, which 
is associated with some symptoms of CD and UC50, is located in intron 17. Whether this 
might affect isoform generation is not clear. However, as processing of the hnRNA occurs 
where multiple steps occur simultaneously, it is possible that even distant changes in 
nucleotide sequence might affect isoform production. These possibilities will be interesting 
to pursue.
The correlation of STAT4β/α mRNA ratios with PCDAI is somewhat unique in that 
correlations with PCDAI are not found with any of the cytokines examined, despite the 
observation that some cytokines are significantly increased in IBD patients. This suggests 
that measuring STAT4β/α mRNA ratios, especially in the peripheral blood, might be a 
useful approach for assessing disease, more so than cytokines that are among the classic 
indicators of inflammation. Measuring STAT4β/α mRNA ratios in the GI tract is limited by 
location. Although ratios in the colon correlated with disease, no correlation was seen with 
STAT4β/α mRNA ratios in other segments. This might be linked to the type of cells that are 
present or recruited to particular segments, or to differing cytokine milieu among the 
segments examined. These possibilities can be explored further.
The observation of increased IL17A mRNA in the esophagus of both CD and UC patients is 
both striking and puzzling. Increased IL17A mRNA was also seen in the colon and rectum of 
CD and UC patients, respectively. However, there are no reports of increased esophageal 
pathology or cytokine expression in patients that do not have esophageal symptoms. It is not 
clear how bowel inflammation would result in altered cytokine expression in the esophagus, 
or why that would specifically be IL17A. IL17A is also increased in samples from patients 
with eosinophilic gastritis or esophageal cancer51, 52, and it is possible that IBD patients 
have some underlying pathology in the esophagus. Importantly, when we examined 14 
patients diagnosed with EoE there was a decrease, not an increase, in IL17A mRNA (data 
not shown). Whether this parameter might be a useful diagnostic tool is not clear.
There are a number of limitations to this study, primarily the relatively small population 
examined. Yet, the statistical significance of the changes observed was clearly apparent. 
Moreover, we were able to detect significant differences in the concentration of serum 
cytokines and in the relative amounts of cytokine mRNA in biopsy tissue, each consistent 
with previous observations in patients with IBD 53. Furthermore, we were able to detect 
changes in STAT4β/α mRNA ratios following treatment, and changes followed the decrease 
in disease. This study focused on a pediatric population because disease onset is more 
uniform in children, and because treatment recommendations, particularly with anti-TNFα 
therapies for recurrent disease, are more limited. However, it is likely that these observations 
would be consistent in adult patients, and it will be interesting to test that hypothesis in 
future studies.
This study highlights a novel biomarker of inflammation in IBD. Measurement of 
STAT4β/α mRNA ratios in PBMCs might be a less invasive approach to monitoring 
inflammation, at least for initial diagnosis. Analyzing STAT4β/α mRNA ratios in biopsies 
or PBMCs might provide some additional prognostic capabilities, perhaps distinguishing 
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how well patients respond to specific therapies. Future analysis of larger patient cohorts will 
determine if STAT4β/α mRNA ratios will have utility in a clinical setting.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Generation of STAT4 isoforms. (A) Schematic of the STAT4 gene. Exons are denoted as 
vertical lines. Red arrows indicate direction of transcription. (B) Schematic of STAT4 
isoforms showing domain structures. ID, interaction domain; coiled, coiled-coil domain; 
DBD, DNA binding domain; TAD, transactivation domain. (C) Schematic of exons 18 and 
19 showing sites of primers (red circles) used for analysis of STAT4 isoforms. Asterisk 
indicates the stop codon for each isoform.
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Figure 2. 
STAT4β/α mRNA expression in biopsies from patients with CD. (A-B) Quantitative 
assessment of total STAT4 and STAT4β/α mRNA expression in regions of gastrointestinal 
tract of newly diagnosed CD patients (n =10) and healthy controls (n =5). (C-F) Quantitative 
assessment of TNFA, IFNG, CSF2 and IL17A mRNA expression in mucosal tissue biopsies 
from regions of the gut of CD patients (n =10) and healthy controls (n =5). Eso, esophagus; 
Sto, stomach; Duod, duodenum; Ile, ileum; Cec, cecum; Col, colon; Rect, rectum. Statistical 
comparisons versus control. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Figure 3. 
STAT4β/α mRNA expression in biopsies from patients with UC. (A-B) Quantitative RT-
PCR analysis of Total STAT4 and STAT4β/α mRNA expression in regions of the 
gastrointestinal tract of newly diagnosed UC patients (n =5) and healthy individuals (n =5). 
(C-F) mRNA expression levels of TNFA, IFNG, CSF2 and IL17A in the mucosal tissue 
biopsies from various regions of the gut of UC patients (n =5) and healthy controls (n =5). 
Eso, esophagus; Sto, stomach; Duod, duodenum; Ile, ileum; Cec, cecum; Col, colon; Rect, 
rectum. Statistical comparisons versus control. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Figure 4. 
PBMCs from CD and UC patients have increased STAT4β/α mRNA ratios. (A-B) PBMCs 
were isolated from both newly diagnosed CD (n =12 and 7 for first and 2nd visit 
respectively) and UC patients (n =12 and 4 first and 2nd visit respectively) and mRNA 
expression levels were measured by RT-PCR. Lines link data points for patients examined at 
both time points (C-D) Average disease scores for CD and UC patients before and after 
steroid treatment respectively. (E-F) PBMCs from established CD (n =9 and 7) or UC (n =7 
and 6, first and 2nd visit respectively) patients were isolated on their first and 2nd visit and 
Jabeen et al. Page 15
Inflamm Bowel Dis. Author manuscript; available in PMC 2016 October 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
expression of total STAT4 and STAT4β/α mRNA was measured by RT-PCR. Statistical 
comparisons versus control. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Figure 5. 
Serum cytokines in CD and UC patients. (A-E) Concentrations of cytokines in the serum of 
newly diagnosed CD and UC patients, established CD and UC patients, and healthy 
controls. Statistical comparisons versus control. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
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Figure 6. 
Correlation of disease score with STAT4β/α mRNA ratios. RNA was isolated from colon 
biopsies of CD patients as described in the methods section and mRNA levels were 
measured. Because of the small n, the p-values were not corrected for multiple comparisons.
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